IRIS
VISCIDO, ANGELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.723
AS - Asia 3.384
EU - Europa 3.322
SA - Sud America 519
AF - Africa 42
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.617
SG - Singapore 1.574
IE - Irlanda 975
CN - Cina 767
DE - Germania 449
BR - Brasile 444
TR - Turchia 394
HK - Hong Kong 393
RU - Federazione Russa 380
IT - Italia 349
SE - Svezia 251
GB - Regno Unito 233
UA - Ucraina 222
FI - Finlandia 176
FR - Francia 96
VN - Vietnam 69
CA - Canada 63
IN - India 54
CZ - Repubblica Ceca 43
AR - Argentina 38
BE - Belgio 32
JP - Giappone 32
PL - Polonia 30
MX - Messico 26
NL - Olanda 24
ES - Italia 19
ZA - Sudafrica 19
ID - Indonesia 18
IQ - Iraq 17
BD - Bangladesh 15
AT - Austria 11
LT - Lituania 11
CO - Colombia 8
EC - Ecuador 7
VE - Venezuela 7
JM - Giamaica 6
MA - Marocco 6
PE - Perù 6
SA - Arabia Saudita 6
AU - Australia 5
AE - Emirati Arabi Uniti 4
EU - Europa 4
IL - Israele 4
JO - Giordania 4
KR - Corea 4
RO - Romania 4
CH - Svizzera 3
CL - Cile 3
CR - Costa Rica 3
GE - Georgia 3
PH - Filippine 3
PK - Pakistan 3
PT - Portogallo 3
TN - Tunisia 3
UZ - Uzbekistan 3
AM - Armenia 2
BG - Bulgaria 2
BS - Bahamas 2
CD - Congo 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BM - Bermuda 1
BO - Bolivia 1
BT - Bhutan 1
CG - Congo 1
CI - Costa d'Avorio 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GA - Gabon 1
GH - Ghana 1
HN - Honduras 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
MK - Macedonia 1
MW - Malawi 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PR - Porto Rico 1
PW - Palau 1
SO - Somalia 1
SR - Suriname 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 14.002
Salva come PNG Salva come JPEG
Città #
Chandler 979
Dublin 965
Jacksonville 942
Dallas 837
Singapore 787
Ashburn 514
Hong Kong 392
Santa Clara 365
Boardman 320
Izmir 197
New York 170
Nanjing 159
San Mateo 151
Lawrence 149
Princeton 149
Wilmington 142
Beijing 135
Ann Arbor 114
Munich 101
Moscow 94
Los Angeles 91
The Dalles 88
Dearborn 76
L'aquila 62
São Paulo 56
Milan 52
Bremen 50
Hefei 44
Woodbridge 42
Columbus 40
Helsinki 40
Seattle 39
Brno 38
Des Moines 37
Shenyang 37
Nanchang 36
Turku 33
Brussels 32
Tianjin 32
Verona 32
Kunming 31
Berlin 28
Shanghai 28
Warsaw 28
Ho Chi Minh City 27
Tokyo 27
London 26
Rome 26
Jinan 25
Montreal 24
Norwalk 24
Phoenix 24
Council Bluffs 21
Frankfurt am Main 21
Lappeenranta 20
Boston 19
Poplar 19
Jiaxing 18
Zhengzhou 18
Brooklyn 17
Mumbai 17
Rio de Janeiro 17
Stockholm 17
Chennai 16
Hebei 16
Falkenstein 15
Belo Horizonte 14
L’Aquila 14
Orem 14
Toronto 14
Amsterdam 13
Brasília 13
Mountain View 13
Changsha 12
Dong Ket 12
Pescara 12
San Francisco 12
Atlanta 11
Fairfield 11
Hanoi 10
Jakarta 10
Manchester 10
Mexico City 10
Ningbo 10
Ankara 9
Denver 9
Fremont 9
Hangzhou 9
Changchun 8
Guangzhou 8
Johannesburg 8
Chicago 7
Auburn Hills 6
Düsseldorf 6
Houston 6
Kingston 6
Nuremberg 6
Pune 6
Querétaro 6
Reggio Nell'emilia 6
Totale 9.518
Salva come PNG Salva come JPEG
Nome #
Efficacia di un nuovo preparato di olio di pesce sulla recidiva del Morbo di Crohn. Giornale di Gastroenterologia 1996;1:158-162 327
The Relationship Between Nutritional Status, Micronutrient Deficiency, and Disease Activity in IBD Patients: A Multicenter Cross-Sectional Study 223
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 154
Subtypes of chronic gastritis in patients with celiac disease before and after gluten-free diet 151
Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms 144
Histological healing in ulcerative colitis with mesalazine and its prognostic role 141
Association between colonic diverticula and colorectal polyps and cancer 138
Subtypes of chronic gastritis in patients with coeliac disease before and after gluten-free diet 136
Mesalazine treatment in organotypic culture of celiac patients: Comparative study with gluten free diet 133
Lymphocytic gastritis is present in Celiac Disease and improves after gluten-free diet. 125
Association between colorectal polyps and colonic diverticulosis 125
Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. 117
The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine 117
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 116
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. 112
Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet 112
Risk of colonoscopic post-polypectomy bleeding in patients on single antiplatelet therapy: systematic review with meta-analysis 112
Colite acuta dopo colonscopia. Giornale di Gastroenterologia 1997; 2: 88-93 110
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? 108
Sleep disorders related to nutrition and digestive diseases: A neglected clinical condition 106
Non-steroidal anti-inflammatory drugs and acetylsalicylic acid increase the risk of complications of diverticular disease: a meta-analysis of case–control and cohort studies 106
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. 105
Survival and causes of death in Italian patients with ulcerative colitis. A GISC nation-wide study. 102
Mucosal healing: Mayo 0 vs 1 after 3 years. 102
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 102
In favour of prophylactic treatment for post-operative recurrence in Crohn's disease. 101
Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea 101
Multicenter validation of the DETAIL questionnaire for the screening of spondyloarthritis in patients with inflammatory bowel diseases 101
Are volatile organic compounds accurate markers in the assessment of colorectal cancer and inflammatory bowel diseases? A review 101
GI distension in severe ulcerative colitis 100
Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) 99
Is fecal calprotectin an accurate marker in the management of Crohn's disease? 99
Can Nrf2 modulate the development of intestinal fibrosis and cancer in inflammatory bowel disease? 99
Inflammatory bowel disease: New insights into the interplay between environmental factors and pparγ 99
Pericarditis after sars‐cov‐2 infection: Another pebble in the mosaic of long covid? 99
Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn's Disease: Do They Still Have a Potential Clinical Role? 99
The role on endoscopy in alcohol-related diseases 98
Current management of severe ulcerative colitis. 98
Italian Group for the Study of the Colon and Rectum: Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study 97
Association between corrected QT interval and C-reactive protein in patients with inflammatory bowel diseases 97
Nanotechnology in the treatment of inflammatory bowel diseases. 97
Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA) concentrations in patients with Crohn's Disease: a GISC study 96
Persistent iron deficiency anemia in patients with celiac disease despite a gluten-free diet 96
The usefulness of serum vitamin D levels in the assessment of IBD activity and response to biologics 96
NK activity and antibody-dependent cellular citotoxicity (ADCC) in inflammatory bowel disease(IBD) 95
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. 95
Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. 94
Safe use of infliximab for the treatment of fistulizing Crohn’s disease during pregnancy within 3 months of conception. 94
Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn's disease: state of the art and review of the literature 93
Duodenal lymphocytosis in functional dyspepsia 93
Celiac disease, gluten-free diet, and metabolic and liver disorders 93
5-ASA enemas increase mucosal availability of mesalamine up to splenic flexure. 92
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 92
Attività NK ed ADCC in pazienti con malattie infiammatorie intestinali (IBD). 91
Small intestine contrast ultrasonography: An alternative to radiology in the assessment of small bowel disease 91
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 91
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis 91
Acute colitis following endoscopy: an outbreak of three cases 90
Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis 90
Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease 89
Recidive stenosanti ricorrenti nel morbo di Crohn. Giornale di Gastroenterologia, 1999, 4: 150-155 89
Association of colonic diverticula with colorectal adenomas and cancer 89
Prognostic factors for post-operative recurrence of Crohn's disease 88
Il 5-ASA (ASACOL) previene le recidive post-operatorie del morbo di crohn (MC): risultati dello studio GISC a tre anni di follow-up. 88
Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. 88
5-ASA enemas increase mucosal availability of mesalamine up to splenic flexure. 88
Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications 88
The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients 87
Acute colitis following colonoscopy 87
Two mesalazine regimens in the prevention of postoperative recurrence of Crohn's disease: A double blind randomised clinical trial. AGISC study. 87
Unmet medical needs in the management of ulcerative colitis: Results of an Italian delphi consensus 87
MRI EVALUATION OF CROHN DISEASE OF THE SMALL AND LARGE BOWEL USING NEGATIVE SUPERPARAMAGNETIC CONTRAST AGENT 86
Is mesalazine treatment effective in the prevention of diverticulitis? A review 86
Site and duration of abdominal pain discriminate symptomatic uncomplicated diverticular disease from previous diverticulitis patients 84
Value of T2-weighted fat suppressed and non suppressed sequences after oral administration of a superparamagnetic contrast agent in the assessmento of Crohn's disease activity 84
Colonic mucosal concentration of 5-ASA in ulcerative colitis. 84
Dietary factors modulating colorectal carcinogenesis 84
Two mesalazine regimens in the prevention of postoperative recurrence of Crohn's disease: A pragmatic double blind randomised controlled trial . Aliment Pharmacol Ther 2003;17:517-523 84
Serum transglutaminase antibodies do not always detect the persistent villous atrophy in patients with celiac disease on a gluten-free diet 84
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations 83
An unusual treatment for a colonic polyp. 83
MRI in Crohn’s disease: assessment of treatment response or relapse 83
Quinidine-induced colitis. Report of three cases. 83
Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment 82
A mathematical model to study natural history of crohn’s disease. 82
L’intestino nei pazienti critici. La barriera mucosa intestinale e le sue alterazioni (prima parte). Giornale di Gastroenterologia 1998; 3: 70-103 82
Immunoglobulin G4-Related Disease of the Intestine: A Clinicopathological Entity to Be Considered 81
CROHN’S DISEASE ACTIVITY INDEX IS INACCURATE TO DETECT THE POSTOPERATIVE RECURRENVCE IN CROHN’S DISEASE 81
Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. 81
A new technique of magnetic resonance imaging (MRI) in the management of patients with Crohn's disease. 81
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 81
Recidiva postoperatoria del morbo di Crohn: un modello matematico per lo studio dell'evoluzione delle lesioni. 80
What are the challenges in selecting pharmacotherapy for pregnant women with inflammatory bowel disease? 80
Persistence of anemia in patients with Celiac disease despite a gluten free diet: a retrospective study 79
Gastrointestinal distension in severe ulcerative colitis 79
Mucosal concentration of 5-ASA in the distal colon. Comparison between oral and plus topical treatment. 79
Fattori di rischio per la recidiva post-operatoria nel morbo di Crohn. 78
CDAI is inadequate for diagnosis of post-operative recurrence of Crohn’s Disease 76
Multiple organ dysfunction complicating severe ulcerative colitis. 76
"Crohn's disease activity index" is inaccurate to detect the post-operative recurrence in Crohn's disease. A GISC study. 76
Totale 9.999
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.752
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.752
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021626 0 0 0 0 0 25 150 17 137 28 232 37
2021/2022799 34 60 94 39 32 27 12 58 43 32 68 300
2022/20232.841 216 159 44 293 257 301 0 204 1.233 16 84 34
2023/2024990 98 28 29 91 47 167 30 285 4 39 51 121
2024/20253.074 69 50 288 98 298 317 382 265 686 180 222 219
2025/20263.000 253 640 602 759 627 119 0 0 0 0 0 0
Totale 14.243